These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29998375)

  • 61. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
    Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
    Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents.
    Truxova I; Hensler M; Skapa P; Halaska MJ; Laco J; Ryska A; Spisek R; Fucikova J
    Int Rev Cell Mol Biol; 2017; 330():115-156. PubMed ID: 28215530
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dendritic cell vaccines for cancer treatment.
    Gabrilovich DI
    Curr Opin Mol Ther; 2002 Oct; 4(5):452-8. PubMed ID: 12435046
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nuclear receptor expression patterns in murine plasmacytoid and conventional dendritic cells.
    Karthaus N; Hontelez S; Looman MW; van Spriel AB; Ansems M; Adema GJ
    Mol Immunol; 2013 Oct; 55(3-4):409-17. PubMed ID: 23597769
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Dendritic cell-based cancer immunotherapy].
    Aruga A
    Nihon Rinsho; 2010 Jun; 68(6):1107-10. PubMed ID: 20535963
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions.
    Zhou J; Li L; Jia M; Liao Q; Peng G; Luo G; Zhou Y
    Cancer Med; 2023 Mar; 12(6):7207-7221. PubMed ID: 36464889
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
    Salem ML
    Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.
    Saxena M; Bhardwaj N
    Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
    Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
    Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.
    Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM
    Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
    Bhargava A; Mishra D; Banerjee S; Mishra PK
    Immunotherapy; 2012 Jul; 4(7):703-18. PubMed ID: 22853757
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Engineering better immunotherapies via RNA interference.
    Sioud M
    Hum Vaccin Immunother; 2014; 10(11):3165-74. PubMed ID: 25483669
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.
    Benencia F; Sprague L; McGinty J; Pate M; Muccioli M
    J Biomed Biotechnol; 2012; 2012():425476. PubMed ID: 22505809
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dendritic Cell Metabolism and Function in Tumors.
    Giovanelli P; Sandoval TA; Cubillos-Ruiz JR
    Trends Immunol; 2019 Aug; 40(8):699-718. PubMed ID: 31301952
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency.
    Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW
    J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.
    Breckpot K; Heirman C; Neyns B; Thielemans K
    J Gene Med; 2004 Nov; 6(11):1175-88. PubMed ID: 15468193
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells.
    Pinho MP; Sundarasetty BS; Bergami-Santos PC; Steponavicius-Cruz K; Ferreira AK; Stripecke R; Barbuto JA
    Cytotherapy; 2016 Apr; 18(4):570-80. PubMed ID: 26971685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.